According to "2016 China medical Device industry Blue Book" disclosed that China's medical devices in 2016 by the export caliber market size of 212.6 billion yuan, of which 99.4 billion yua

Medical network October 31, Mindray Medical released the first three quarterly reports on October 29 night after the listing. 2018 years ago in the three quarter, Mai Rui medical revenue 10.28 billion yuan, an increase of 23.19%, achieve net profit of 2.897 billion yuan, an increase of 45.27%, deduction of non-recurrent profit and loss after the net profit of 2.845 billion yuan, an increase of 41.42%, are in line with expectations.

The company's three quarterly reports also showed that 2018 years ago, three quarters of the company invested 969 million yuan in research and development, compared with the same period last year, a significant increase of 754 million yuan accounted for more than three of the first 9% quarter revenue. The company disclosed in the October 15 listing notice, benefiting from the medical device market continued stable growth and the company in research and development, production, marketing and other aspects of competitive advantage, 2018 1-September, the company expects operating income of 10.1 billion yuan-10.45 billion yuan, an increase of 21.03%-25.23%; Net profit is expected to be 2.8 billion yuan-3 billion yuan, an increase of 40.42%-50.45%;

It is expected to deduct the net profit of 2.75 billion yuan-2.95 billion yuan, up 36.67%-46.61% yoy. Mindray's main business is the development, manufacture and marketing of medical devices. The company was founded in 1999, in 2006, the NYSE, 2015 as a member of the privatization of the Chinese share of the return from the New York City, October 16, 2018, Mai Rui medical official in the Shenzhen Stock Exchange Business

Board of listed transactions, its fundraising total of 5.93 billion yuan, for the gem of the largest ever IPO. The announcement also showed that the annual revenue of the Swiss medical service in 2018 was $13 billion-$ 14.3 billion, an increase of 16.34% to 27.98% over a year earlier; The net profit is expected to be $3.32 billion-$ 4.06 billion, an increase of 28.68%-57.36% over a year earlier. The company said that the main reason for the growth of product sales to achieve high growth, sales revenue stable growth;

Company control fee Drop this, management efficiency improvement. According to an investigation of security securities, it is generally found that the test results of domestic instruments and foreign products ' no difference ', most Hospital are inclined to Purchase Domestically produced products, with the technical upgrading of domestic manufacturers, high-end Medical devices Equipment Industry Domestic Enterprise Will usher in import substitution opportunities.